 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 1432908-05-8 |
| Molecular formula(MF) | C28H32ClN7O |
| Molecular Weight(MW): | 518.05 |
| Alias |
| In vitro | Ethanol | 20 mg/mL (38.6 mM) |
|---|---|---|
| DMSO | <1 mg/mL | |
| Water | <1 mg/mL | |
| In vivo |
| Description | FRAX-1036 is a potent and selective PAK1 inhibitor. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
||||||
| In vitro |
Potent cellular inhibition of group I PAK substrate phosphorylation (MEK1-S298 and CRAF-S338) was observed at 2.5 to 5 μM concentrations of FRAX1036 in PAK1-amplified MDA-MB-175 cells. Treatment of PAK1-amplified breast cancer cells with FRAX1036 results in apoptosis[1]. And treatment of OVCAR-3 cells with FRAX-1036 results in upregulation of p53 and p21, while down-regulating cyclin B1[3]. |
||||||
| In vivo | Treatment with Frax1036 results in slower KT21 tumor growth and is unlikely to have significant blood brain barrier permeability in mice[4]. |